• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    9/4/25 4:15:40 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    8-K
    false 0001136869 0001136869 2025-09-04 2025-09-04 0001136869 us-gaap:CommonStockMember 2025-09-04 2025-09-04 0001136869 zbh:M2.425NotesDue2026Member 2025-09-04 2025-09-04 0001136869 zbh:M1.164NotesDue2027Member 2025-09-04 2025-09-04 0001136869 zbh:M3.518NotesDue2032Member 2025-09-04 2025-09-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 4, 2025

     

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-16407   13-4151777
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    345 East Main Street  
    Warsaw, Indiana   46580
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (574) 373-3333

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

      

    Trading
    Symbol(s)

      

    Name of each exchange
    on which registered

    Common Stock, $0.01 par value    ZBH    New York Stock Exchange
    2.425% Notes due 2026    ZBH 26    New York Stock Exchange
    1.164% Notes due 2027    ZBH 27    New York Stock Exchange
    3.518% Notes due 2032    ZBH 32    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01

    Other Events.

    On September 4, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued two new series of senior unsecured debt securities denominated in Swiss francs, comprising CHF 210,000,000 aggregate principal amount of the Company’s 0.930% Bonds 2025 – 2030 (the “Tranche A Bonds”) and CHF 390,000,000 aggregate principal amount of the Company’s 1.560% Bonds 2025 – 2035 (the “Tranche B Bonds” and, together with the Tranche A Bonds, the “Bonds”).

    The Bonds were issued pursuant to a bond purchase and paying agency agreement, dated September 2, 2025 (the “BPPAA”), by and among the Company and certain financial institutions, as the joint lead managers.

    The Bonds bear interest at a rate of 0.930% per annum in the case of the Tranche A Bonds and 1.560% per annum in the case of the Tranche B Bonds, which interest, in each case, will be payable annually in arrears on September 4 of each year, commencing on September 4, 2026. The Tranche A Bonds mature on September 4, 2030 and the Tranche B Bonds mature on September 4, 2035.

    The Company will, subject to certain exceptions and limitations, pay additional amounts on the Bonds as are necessary in order that the net payment of the principal of, and premium, if any, and interest on, the Bonds to a holder who is not a United States person, after any required withholding or deduction for, or on account of, any present or future taxes, duties, assessments or governmental charges imposed or levied by the United States, any political subdivision thereof or any taxing authority thereof or therein, will not be less than the amount provided in the Bonds to be then due and payable. In the event that certain developments affecting United States taxation would cause the Company to pay such additional amounts, the Company will have the option to redeem the Bonds, in whole, but not in part, at par.

    Each tranche of the Bonds is subject to “3-months par call” and “clean-up call” provisions, pursuant to which the Company may redeem such tranche in whole, but not in part, at par at any time (a) on or after June 4, 2030 in the case of the Tranche A Bonds or June 4, 2035 in the case of the Tranche B Bonds, or (b) if 85% or more of the aggregate principal amount of such tranche has been redeemed or purchased and cancelled.

    Holders of the Bonds will also have the option to require the Company to repurchase, at par, all or any of such holder’s Bonds upon the occurrence of a Change of Control Triggering Event, as defined in the instruments governing the Bonds.

    The BPPAA provides for customary events of default, including, among other things, nonpayment, failure to comply with the other covenants, warranties and agreements in the BPPAA for a period of 60 days after notice thereof, and certain events of bankruptcy, insolvency and reorganization.

    The description set forth above does not purport to be a complete description of the terms and conditions of the Bonds.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: September 4, 2025

     

    ZIMMER BIOMET HOLDINGS, INC.
    By:  

    /s/ Chad F. Phipps

    Name:   Chad F. Phipps
    Title:   Senior Vice President, General Counsel
    and Secretary
    Get the next $ZBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    More analyst ratings

    $ZBH
    SEC Filings

    View All

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    9/4/25 4:15:40 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    8/13/25 4:53:23 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

    10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    8/7/25 4:06:20 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet upgraded by Roth Capital with a new price target

    Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00

    7/15/25 8:30:57 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet upgraded by Analyst with a new price target

    Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

    12/17/24 8:26:36 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Wolfe Research initiated coverage on Zimmer Biomet

    Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

    9/10/24 8:03:41 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Showcase Foot and Ankle Portfolio at the American Orthopedic Foot and Ankle Society Annual Conference

    WARSAW, Ind., Sept. 4, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its participation in the American Orthopedic Foot and Ankle Society Annual Conference in Savannah, Ga. From September 10-13, 2025, Zimmer Biomet's wholly owned subsidiary, Paragon 28, will feature a suite of industry-leading foot and ankle products. "We are excited to engage with foot and ankle specialists at AOFAS and highlight our latest innovations in what's been a remarkably strong cadence of product launches over the past two ye

    9/4/25 4:05:00 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2025

    WARSAW, Ind., Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.

    8/27/25 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Controller, CAO Stellato Paul A covered exercise/tax liability with 402 shares and converted options into 1,281 shares, increasing direct ownership by 31% to 3,710 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/2/25 4:09:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SVP and CHRO Winkler Lori sold $153,735 worth of shares (1,500 units at $102.49), decreasing direct ownership by 15% to 8,333 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    8/20/25 4:04:40 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Grp Pres-Global Bus. Thornal Kevin R

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    8/13/25 4:15:14 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2025

    WARSAW, Ind., Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.

    8/27/25 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

    WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so

    7/9/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care